Bladder cancer

James E. Montie, Peter E. Clark, Mario A. Eisenberger, Rizk El-Galley, Richard E. Greenberg, Harry W. Herr, Gary R. Hudes, Deborah A. Kuban, Timothy M. Kuzel, Paul H. Lange, Subodh M. Lele, Jeffrey Michalski, Anthony Patterson, Kamal S. Pohar, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Donald L. Trump, Phillip J. Walther & 1 others Timothy G. Wilson

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Urothelial tumors represent a spectrum of diseases with a range of prognoses. After a tumor is diagnosed anywhere within the urothelial tract, the patient remains at risk for developing a new lesion at a different location, or at the same location and with a similar or more advanced stage. Continued monitoring for recurrence is an essential part of management because most recurrences are superficial and can be treated endoscopically. Within each category of disease, more refined methods to determine prognosis and guide management, based on molecular staging, are under development with the goal of optimizing each patient's likelihood of cure and chance for organ preservation. For patients with more extensive disease, newer treatments typically involve combined modality approaches using recently developed surgical procedures, or 3-dimensional treatment planning for more precise delivery of radiation therapy. Although these are not appropriate in all cases, they offer the promise of an improved quality of life and prolonged survival. Finally, within the category of metastatic disease, several new agents have been identified that seem superior to those currently considered standard therapies. Experts believe, therefore, that the treatment of urothelial tumors will evolve rapidly over the next few years, with improved outcomes for patients at all stages of disease.

Original languageEnglish (US)
Pages (from-to)8-38
Number of pages31
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume7
Issue number1
StatePublished - Jan 1 2009

Fingerprint

Urinary Bladder Neoplasms
Organ Preservation
Recurrence
Neoplasms
Therapeutics
Radiotherapy
Quality of Life
Survival

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Montie, J. E., Clark, P. E., Eisenberger, M. A., El-Galley, R., Greenberg, R. E., Herr, H. W., ... Wilson, T. G. (2009). Bladder cancer. JNCCN Journal of the National Comprehensive Cancer Network, 7(1), 8-38.

Bladder cancer. / Montie, James E.; Clark, Peter E.; Eisenberger, Mario A.; El-Galley, Rizk; Greenberg, Richard E.; Herr, Harry W.; Hudes, Gary R.; Kuban, Deborah A.; Kuzel, Timothy M.; Lange, Paul H.; Lele, Subodh M.; Michalski, Jeffrey; Patterson, Anthony; Pohar, Kamal S.; Richie, Jerome P.; Sexton, Wade J.; Shipley, William U.; Small, Eric J.; Trump, Donald L.; Walther, Phillip J.; Wilson, Timothy G.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 7, No. 1, 01.01.2009, p. 8-38.

Research output: Contribution to journalArticle

Montie, JE, Clark, PE, Eisenberger, MA, El-Galley, R, Greenberg, RE, Herr, HW, Hudes, GR, Kuban, DA, Kuzel, TM, Lange, PH, Lele, SM, Michalski, J, Patterson, A, Pohar, KS, Richie, JP, Sexton, WJ, Shipley, WU, Small, EJ, Trump, DL, Walther, PJ & Wilson, TG 2009, 'Bladder cancer', JNCCN Journal of the National Comprehensive Cancer Network, vol. 7, no. 1, pp. 8-38.
Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW et al. Bladder cancer. JNCCN Journal of the National Comprehensive Cancer Network. 2009 Jan 1;7(1):8-38.
Montie, James E. ; Clark, Peter E. ; Eisenberger, Mario A. ; El-Galley, Rizk ; Greenberg, Richard E. ; Herr, Harry W. ; Hudes, Gary R. ; Kuban, Deborah A. ; Kuzel, Timothy M. ; Lange, Paul H. ; Lele, Subodh M. ; Michalski, Jeffrey ; Patterson, Anthony ; Pohar, Kamal S. ; Richie, Jerome P. ; Sexton, Wade J. ; Shipley, William U. ; Small, Eric J. ; Trump, Donald L. ; Walther, Phillip J. ; Wilson, Timothy G. / Bladder cancer. In: JNCCN Journal of the National Comprehensive Cancer Network. 2009 ; Vol. 7, No. 1. pp. 8-38.
@article{bc029535a326454c878fc36769d781ff,
title = "Bladder cancer",
abstract = "Urothelial tumors represent a spectrum of diseases with a range of prognoses. After a tumor is diagnosed anywhere within the urothelial tract, the patient remains at risk for developing a new lesion at a different location, or at the same location and with a similar or more advanced stage. Continued monitoring for recurrence is an essential part of management because most recurrences are superficial and can be treated endoscopically. Within each category of disease, more refined methods to determine prognosis and guide management, based on molecular staging, are under development with the goal of optimizing each patient's likelihood of cure and chance for organ preservation. For patients with more extensive disease, newer treatments typically involve combined modality approaches using recently developed surgical procedures, or 3-dimensional treatment planning for more precise delivery of radiation therapy. Although these are not appropriate in all cases, they offer the promise of an improved quality of life and prolonged survival. Finally, within the category of metastatic disease, several new agents have been identified that seem superior to those currently considered standard therapies. Experts believe, therefore, that the treatment of urothelial tumors will evolve rapidly over the next few years, with improved outcomes for patients at all stages of disease.",
author = "Montie, {James E.} and Clark, {Peter E.} and Eisenberger, {Mario A.} and Rizk El-Galley and Greenberg, {Richard E.} and Herr, {Harry W.} and Hudes, {Gary R.} and Kuban, {Deborah A.} and Kuzel, {Timothy M.} and Lange, {Paul H.} and Lele, {Subodh M.} and Jeffrey Michalski and Anthony Patterson and Pohar, {Kamal S.} and Richie, {Jerome P.} and Sexton, {Wade J.} and Shipley, {William U.} and Small, {Eric J.} and Trump, {Donald L.} and Walther, {Phillip J.} and Wilson, {Timothy G.}",
year = "2009",
month = "1",
day = "1",
language = "English (US)",
volume = "7",
pages = "8--38",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "1",

}

TY - JOUR

T1 - Bladder cancer

AU - Montie, James E.

AU - Clark, Peter E.

AU - Eisenberger, Mario A.

AU - El-Galley, Rizk

AU - Greenberg, Richard E.

AU - Herr, Harry W.

AU - Hudes, Gary R.

AU - Kuban, Deborah A.

AU - Kuzel, Timothy M.

AU - Lange, Paul H.

AU - Lele, Subodh M.

AU - Michalski, Jeffrey

AU - Patterson, Anthony

AU - Pohar, Kamal S.

AU - Richie, Jerome P.

AU - Sexton, Wade J.

AU - Shipley, William U.

AU - Small, Eric J.

AU - Trump, Donald L.

AU - Walther, Phillip J.

AU - Wilson, Timothy G.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Urothelial tumors represent a spectrum of diseases with a range of prognoses. After a tumor is diagnosed anywhere within the urothelial tract, the patient remains at risk for developing a new lesion at a different location, or at the same location and with a similar or more advanced stage. Continued monitoring for recurrence is an essential part of management because most recurrences are superficial and can be treated endoscopically. Within each category of disease, more refined methods to determine prognosis and guide management, based on molecular staging, are under development with the goal of optimizing each patient's likelihood of cure and chance for organ preservation. For patients with more extensive disease, newer treatments typically involve combined modality approaches using recently developed surgical procedures, or 3-dimensional treatment planning for more precise delivery of radiation therapy. Although these are not appropriate in all cases, they offer the promise of an improved quality of life and prolonged survival. Finally, within the category of metastatic disease, several new agents have been identified that seem superior to those currently considered standard therapies. Experts believe, therefore, that the treatment of urothelial tumors will evolve rapidly over the next few years, with improved outcomes for patients at all stages of disease.

AB - Urothelial tumors represent a spectrum of diseases with a range of prognoses. After a tumor is diagnosed anywhere within the urothelial tract, the patient remains at risk for developing a new lesion at a different location, or at the same location and with a similar or more advanced stage. Continued monitoring for recurrence is an essential part of management because most recurrences are superficial and can be treated endoscopically. Within each category of disease, more refined methods to determine prognosis and guide management, based on molecular staging, are under development with the goal of optimizing each patient's likelihood of cure and chance for organ preservation. For patients with more extensive disease, newer treatments typically involve combined modality approaches using recently developed surgical procedures, or 3-dimensional treatment planning for more precise delivery of radiation therapy. Although these are not appropriate in all cases, they offer the promise of an improved quality of life and prolonged survival. Finally, within the category of metastatic disease, several new agents have been identified that seem superior to those currently considered standard therapies. Experts believe, therefore, that the treatment of urothelial tumors will evolve rapidly over the next few years, with improved outcomes for patients at all stages of disease.

UR - http://www.scopus.com/inward/record.url?scp=58149348348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149348348&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 8

EP - 38

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 1

ER -